Glioblastoma is an aggressive and heterogeneous tumor in which glioblastoma stem cells
(GSCs) are at the apex of an entropic hierarchy and impart devastating therapy resistance …

Anti-angiogenic therapy is one of the promising strategies for many types of solid cancers.
Bevacizumab (Avastin), a recombinant humanized monoclonal antibody of vascular …

Limiting dietary carbohydrates inhibits glioma growth in preclinical models. Therefore, the
ERGO trial (NCT00575146) examined feasibility of a ketogenic diet in 20 patients with …

Glioblastoma (GBM) is the most common and lethal intracranial malignancy, with few
advances in treatment over the last several decades. Much excitement surrounded the initial …

Antiangiogenic therapy is associated with increased radiographic responses in
glioblastomas, but tumors invariably recur. Because tumor-associated macrophages have …

Glioblastoma (GBM) is a hypervascular neoplasia of the central nervous system with an
extremely high rate of mortality. Owing to its hypervascularity, anti-angiogenic therapies …

Anti-VEGF therapy prolongs recurrence-free survival in patients with glioblastoma but does
not improve overall survival. To address this discrepancy, we investigated immunologic …

Purpose: To identify mediators of glioblastoma antiangiogenic therapy resistance and target
these mediators in xenografts. Experimental Design: We conducted microarray analysis …

Glioblastoma is characterized by high expression levels of proangiogenic cytokines and
microvascular proliferation, highlighting the potential value of treatments targeting …

Antiangiogenic therapies like bevacizumab offer promise for cancer treatment, but acquired
resistance, which often includes an aggressive mesenchymal phenotype, can limit the use of …